These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21479093)

  • 1. Potential impact of single-risk-factor versus total risk management for the prevention of cardiovascular events in Seychelles.
    Ndindjock R; Gedeon J; Mendis S; Paccaud F; Bovet P
    Bull World Health Organ; 2011 Apr; 89(4):286-95. PubMed ID: 21479093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of cardiovascular risk factors in a middle-income country and estimated cost of a treatment strategy.
    Bovet P; Shamlaye C; Gabriel A; Riesen W; Paccaud F
    BMC Public Health; 2006 Jan; 6():9. PubMed ID: 16423280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Divergent fifteen-year trends in traditional and cardiometabolic risk factors of cardiovascular diseases in the Seychelles.
    Bovet P; Romain S; Shamlaye C; Mendis S; Darioli R; Riesen W; Tappy L; Paccaud F
    Cardiovasc Diabetol; 2009 Jun; 8():34. PubMed ID: 19558646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study.
    Lin JK; Moran AE; Bibbins-Domingo K; Falase B; Pedroza Tobias A; Mandke CN; Kazi DS
    Lancet Glob Health; 2019 Oct; 7(10):e1346-e1358. PubMed ID: 31477544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK.
    Becerra V; Gracia A; Desai K; Abogunrin S; Brand S; Chapman R; García Alonso F; Fuster V; Sanz G
    BMJ Open; 2015 May; 5(5):e007111. PubMed ID: 25991449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.
    Villa G; Lothgren M; Kutikova L; Lindgren P; Gandra SR; Fonarow GC; Sorio F; Masana L; Bayes-Genis A; Hout BV
    Clin Ther; 2017 Apr; 39(4):771-786.e3. PubMed ID: 28366593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
    Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
    Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project.
    van den Oever IAM; Heslinga M; Griep EN; Griep-Wentink HRM; Schotsman R; Cambach W; Dijkmans BAC; Smulders YM; Lems WF; Boers M; Voskuyl AE; Peters MJL; van Schaardenburg D; Nurmohamed MT
    Rheumatology (Oxford); 2017 Sep; 56(9):1472-1478. PubMed ID: 28199724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The social transition of risk factors for cardiovascular disease in the African region: evidence from three cross-sectional surveys in the Seychelles.
    Stringhini S; Viswanathan B; Gédéon J; Paccaud F; Bovet P
    Int J Cardiol; 2013 Sep; 168(2):1201-6. PubMed ID: 23206526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Framingham-Based Cardiovascular Risk Estimates Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study.
    Lipton RB; Reed ML; Kurth T; Fanning KM; Buse DC
    Headache; 2017 Nov; 57(10):1507-1521. PubMed ID: 28990165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total cardiovascular risk assessment and management using two prediction tools, with and without blood cholesterol.
    Nordet P; Mendis S; Dueñas A; de la Noval R; Armas N; de la Noval IL; Pupo H
    MEDICC Rev; 2013 Oct; 15(4):36-40. PubMed ID: 24253349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.
    Ramsey SD; Clarke LD; Roberts CS; Sullivan SD; Johnson SJ; Liu LZ
    Pharmacoeconomics; 2008; 26(4):329-39. PubMed ID: 18370567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Asheville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia.
    Bunting BA; Smith BH; Sutherland SE
    J Am Pharm Assoc (2003); 2008; 48(1):23-31. PubMed ID: 18192127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular Events, Conditions, and Procedures Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study.
    Buse DC; Reed ML; Fanning KM; Kurth T; Lipton RB
    Headache; 2017 Jan; 57(1):31-44. PubMed ID: 27861837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determining initial and follow-up costs of cardiovascular events in a US managed care population.
    Chapman RH; Liu LZ; Girase PG; Straka RJ
    BMC Cardiovasc Disord; 2011 Mar; 11():11. PubMed ID: 21410963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
    Boersma C; Gansevoort RT; Pechlivanoglou P; Visser ST; van Toly FF; de Jong-van den Berg LT; de Jong PE; Postma MJ;
    Clin Ther; 2010 Jun; 32(6):1103-21. PubMed ID: 20637965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context.
    Toth PP; Danese M; Villa G; Qian Y; Beaubrun A; Lira A; Jansen JP
    J Med Econ; 2017 Jun; 20(6):555-564. PubMed ID: 28097904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
    Whitfield MD; Gillett M; Holmes M; Ogden E
    Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A polypill strategy to improve adherence: results from the FOCUS project.
    Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
    J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs associated with renal and cardiovascular events among patients with type 2 diabetes mellitus and nephropathy: a cost model based on the CREDENCE clinical trial.
    Manceur AM; Durkin M; Kharat A; Bookhart B; Lafeuille MH; Pilon D; Fakih I; Lefebvre P
    Curr Med Res Opin; 2020 Apr; 36(4):563-570. PubMed ID: 31916465
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.